While the expanded access is clearly positive for Novo Nordisk, the broader competitive implications are more nuanced. Eli Lilly’s (LLY Quick QuoteLLY<\/a> – Free Report<\/a>) GLP-1 obesity drugs \u2014 Zepbound (tirzepatide) injection and Foundayo (orforglipron) pill \u2014 are now also available under the same Medicare GLP-1 Bridge program at the identical $50 monthly copay. As a result, Medicare reimbursement is unlikely to become a differentiating factor between the two obesity leaders. Instead, the program largely levels the playing field by removing affordability as a key barrier for eligible Medicare patients, shifting competition back to product characteristics, physician preference and clinical differentiation.<\/p>\n This matters because Lilly has steadily gained share in the obesity market over the past year. Zepbound has outperformed Wegovy injection in head-to-head weight-loss studies, making it an increasingly attractive option for physicians seeking greater efficacy. With Medicare patients now receiving similar reimbursement for both therapies, Novo Nordisk cannot rely on broader insurance access alone to defend market share in injectables. The competitive battle will increasingly hinge on clinical outcomes and long-term real-world experience rather than pricing or reimbursement advantages.<\/p>\n The same dynamic is beginning to emerge in oral obesity therapy. Novo Nordisk enjoyed a first-mover advantage after launching the Wegovy pill earlier this year, helping the product rapidly exceed three million prescriptions. However, Lilly’s Foundayo introduces meaningful competition with a simpler administration profile. Unlike the Wegovy pill, which must be taken on an empty stomach under specific dosing instructions, Foundayo can be taken without food or drink restrictions, offering greater day-to-day convenience that could improve patient adherence.<\/p>\n That said, convenience is only one side of the equation. Clinical data suggest the Wegovy pill carries a relatively lower burden of gastrointestinal side effects than Foundayo, which could influence prescribing decisions. As a result, some physicians and patients may prefer the Wegovy pill for its better tolerability, even if Foundayo is more convenient to take.<\/p>\n Overall, the Medicare GLP-1 Bridge program should expand the addressable obesity market by improving affordability for millions of eligible beneficiaries rather than materially favoring one manufacturer over the other. For Novo Nordisk, the expanded access supports continued prescription growth and validates the commercial opportunity for its obesity franchise. However, because Lilly’s competing injectable and oral products receive the same reimbursement benefit, the program does little to alter the competitive landscape.<\/p>\n Going forward, NVO\u2019s ability to stabilize and eventually regain obesity market share will depend less on reimbursement expansion and more on differentiating Wegovy through its broader clinical profile. Beyond weight loss, Wegovy remains the only obesity therapy approved to reduce the risk of major adverse cardiovascular events in adults with obesity and established cardiovascular disease, a benefit that continues to strengthen its value proposition as physicians increasingly weigh efficacy, safety and long-term clinical outcomes alongside patient convenience.<\/p>\n Competition Heating Up in the GLP-1 Space for NVO<\/p>\n While Novo Nordisk and Eli Lilly presently dominate the obesity market, smaller biotech firms, like\u00a0Viking Therapeutics\u00a0(VKTX Quick QuoteVKTX<\/a> – Free Report<\/a>) and Structure Therapeutics\u00a0(GPCR Quick QuoteGPCR<\/a> – Free Report<\/a>) , are also advancing GLP-1\u2013based therapies to challenge the incumbents.<\/p>\n Viking Therapeutics\u2019 dual GIPR\/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity.\u00a0Viking Therapeutics plans to advance oral VK2735 into phase III development for obesity in the fourth quarter of 2026.<\/p>\n Structure Therapeutics\u2019 phase II ACCESS study on its orally administered GLP-1 RA, aleniglipron, demonstrated significant weight loss across all doses. Structure Therapeutics expects to initiate the late-stage program of aleniglipron in obesity in the second half of 2026.<\/p>\n NVO\u2019s Stock Price, Valuation & Estimates<\/p>\n
![\"Zacks](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/07\/169757.jpg\"\/)
Image Source: Zacks Investment Research<\/p>\n![\"Zacks](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/07\/169758.jpg\"\/)
Image Source: Zacks Investment Research<\/p>\n![\"Zacks](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/07\/169759.jpg\"\/)
Image Source: Zacks Investment Research<\/p>\n